Drug Pricing Practices In Canada, Germany May Stifle Innovation – USTR
Executive Summary
Drug pricing practices in Canada and Germany have the potential to stifle pharmaceutical innovation, the U.S. Trade Representative's "Special 301" report on intellectual property protection suggests